Genprex, INC DEF 14A proxy statements

Genprex, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to address key corporate matters including director elections, auditor ratification, executive compensation, and a proposed reverse stock split.

Genprex, Inc. reports significant progress in its oncology and diabetes gene therapy programs, including clinical trial advancements and intellectual property expansion, with key milestones expected in 2026.

Genprex, Inc. is calling its 2025 Annual Meeting of Stockholders to vote on critical proposals including a reverse stock split to regain Nasdaq compliance, an equity incentive plan amendment, and approval for a significant common stock issuance to Lincoln Park Capital Fund, LLC.

Genprex, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Genprex, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, to vote on director election, auditor ratification, executive compensation, and say-on-pay frequency.